Business Context and Reporting Period
This Form 8-K Current Report was filed by Calidi Biotherapeutics, Inc. (CLDI) on May 16, 2024, covering an event that occurred on May 10, 2024. The Company is a Delaware corporation incorporated as an emerging growth company, with principal executive offices in San Diego, California.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes rather than financial performance.
Material Changes
The primary material change reported is the departure of a director:
- Resignation: Mr. David LaPre resigned as a director of the Company and from all Board committees on which he served, effective immediately on May 10, 2024.
- Reason: The resignation was not the result of any dispute or disagreement with the Company or its Board regarding operations, policies, or practices.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies beyond the standard disclosure regarding the director's resignation.
Investor Verification Checklist
- Verify the current composition of the Board of Directors following Mr. LaPre's immediate resignation.
- Confirm whether the Company intends to appoint a replacement director to fill the vacancy.
- Review subsequent filings for any impact on Board committee structures or quorum requirements.